Izabela G.
- Country
- Poland
- Department
- Centrum Badań Klinicznych
Research Overview
- Phase 3 Randomized, Double-Blind Study of Niraparib, Abiraterone Acetate, and Prednisone in HRR Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer
- Phase II Randomized Study of Trastuzumab Deruxtecan vs. CDK4/6 Inhibitor-Based Endocrine Therapy in HR-Positive, HER2-Low/Ultra-Low Advanced Breast Cancer
Data & Insights
Has run more than one trial at 11 of 128 partner sites.
Specializations
Oncological Focus
This investigator specializes in the treatment of metastatic castration-sensitive prostate cancer, with particular emphasis on cases involving homologous recombination repair (HRR) gene mutations.
- Prostate Cancer Treatment
- Genetic Mutation Analysis
- Metastatic Disease Management
The research focus extends to both germline and somatic mutations in prostate cancer patients.
Therapeutic Innovation
The investigator explores combination therapy approaches in advanced prostate cancer treatment, integrating novel therapeutic agents with established treatment protocols.
- Combination Therapy Development
- Treatment Response Assessment
- Clinical Efficacy Studies
Their work encompasses the evaluation of therapeutic interventions in hormone-sensitive prostate cancer.
Precision Medicine
The investigator's expertise includes the application of precision medicine approaches in treating genetically characterized prostate cancer.
- Genetic Profiling
- Targeted Therapy
- Personalized Treatment Strategies
Their research focuses on tailoring treatments based on specific genetic mutations in prostate cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.